艾立布林单药或联合方案治疗晚期成人软组织肉瘤的疗效及安全性分析

Effi cacy and safety of eribulin or combination regimen in treatment of advanced adult soft tissue sarcoma

目的探讨艾立布林方案治疗晚期成人软组织肉瘤的疗效及安全性。方法回顾性分析20例接受艾立布林单药或联合方案姑息治疗的晚期成人软组织肉瘤患者的疗效和安全性。结果20例患者中,部分缓解3例,疾病稳定7例,疾病进展10例,客观有效率为15.0%(3/20),疾病控制率为50.0%(10/20),中位无进展生存时间为2.5个月。3例部分缓解患者均为脂肪肉瘤,中位缓解持续时间为2.5个月。艾立布林单药组(n=7)与联合治疗组(n=13)的客观缓解率、疾病控制率和中位无进展生存时间比较,差异均无统计学意义(均P>0.05)。艾立布林在由脂肪肉瘤和平滑肌肉瘤组成的L型肉瘤中疗效确切。常见不良反应有骨髓抑制、乏力、口腔溃疡和甘油三酯升高。无治疗相关死亡。结论艾立布林单药或联合方案治疗晚期软组织肉瘤的疗效肯定,不良反应可耐受,尤其在L型肉瘤中疗效显著,但疗效不够持久,值得开展研究探索前线应用及联合治疗策略。

Objective To investigate the efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma(STS).Methods Twenty patients with advanced adult STS who received eribulin(n=7)or combined palliative treatment(n=13)were selected.The efficacy and safety of these patients were retrospectively analyzed.Results Among the 20 patients,3 had partial response,7 had disease stability,10 had disease progression,the overall response rate(ORR)was 15.0%(3/20),the disease control rate(DCR)was 50.0%(10/20),and the median progression-free survival(PFS)was 2.5 months.Three patients with partial response were diagnosed as liposarcoma and the median duration of response was 2.5 months.There were no significant differences in ORR,DCR and median PFS between the eribulin alone group and the combination regimen group(all P>0.05).Eribulin showed promising therapeutic effect on L-type sarcoma,including liposarcoma and leiomyosarcoma.Common adverse events included bone marrow suppression,fatigue,oral ulcers and hypertriglyceridemia.There were no treatment-related deaths.Conclusions Eribulin alone and combination regimen are both effective and tolerable in the treatment of advanced STS,especially in L-type sarcoma.Meanwhile the effect is not durable.It is worth of further clinical exploration of front-line use and combination treatment strategies.